|
Resolution: standard / high Figure 2.
Modulation of E-cadherin expression in MCF-7 cell using siRNA. (a) MCF-7 cells were left untreated (control, 'C') or treated with transfection lipid
('L'), non-targeting (scrambled) siRNA ('NT') or E-cadherin-specific siRNA ('CDH1')
for the times indicated in the presence or absence of tamoxifen. Cells were then lysed
and the lysates probed for E-cadherin. (b) Densitometry analysis was performed on three separate sample sets and plotted as mean
percentage change ± standard deviations *p < 0.05 versus control. siRNA treatment
significantly inhibited E-cadherin expression over a period of 72 hours irrespective
of the presence of tamoxifen. (c) To determine whether E2 or tamoxifen-modulated E-cadherin expression, cells were treated
with E2 or tamoxifen, lysed and probed for E-cadherin and β-actin. Neither E2 nor
tamoxifen significantly altered E-cadherin expression in these cells. (d) MCF-7 cells were treated with plain medium (oestrogen free) or CDH1 siRNA for 72 hours
in the presence or absence of tamoxifen before immunofluorescence staining of E-cadherin
(green) and actin (red). Cells were then visualised by fluorescence microscopy and
representative pictures taken of the same field of view using fluorescein isothiocyanate
(FITC) and TRITC (Tetramethyl rhodamine isothiocyanate) filters. Very little or no
E-cadherin was detectable after siRNA treatment. Inclusion of tamoxifen alongside
the siRNA appeared to increase the numbers of cells having a spherical morphology.
Borley et al. Breast Cancer Research 2008 10:R103 doi:10.1186/bcr2206 |